Penumbra PEN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Embolization and Other | $455.75M+20.2% | $379.14M-0.5% | $381.18M+13.4% | $336M+8.5% | |
| Thrombectomy | $947.92M+16.2% | $815.48M+20.4% | $677.34M+32.5% | $511.14M+16.8% | |
| Revenue by Geography | |||||
| United States | $1.09B+21.0% | $902.07M+19.1% | $757.15M+28.0% | $591.72M+12.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Penumbra break its business down?
- Penumbra (PEN) reports revenue by product across 3 parts — Embolization and Access, Embolization and Other and Thrombectomy. Each is extracted from the segment footnotes and tracked over time.
- Where does Penumbra's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Penumbra's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
